PolyPid Ltd. — FY2020 Form 20-F
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter financial update. Figures are in U.S. dollars unless indicated; financial statement amounts are generally reported in thousands.
Business context
PolyPid is an Israeli Phase 3 clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its proprietary PLEX platform is intended to deliver drugs locally over an extended period. Lead candidate D-PLEX 100, combining PLEX with doxycycline, is being developed to prevent surgical site infections (SSIs). Ordinary shares trade on Nasdaq as PYPD.
Financial results and position
| Metric | FY2020 / Dec. 31, 2020 | FY2019 / Dec. 31, 2019 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense, net | $16.954 million | $14.083 million |
| Marketing and business development expense | $1.614 million | $0.887 million |
| General and administrative expense | $7.704 million | $3.590 million |
| Operating loss | $26.272 million | $18.560 million |
| Net loss | $36.869 million | $6.905 million |
| Net cash used in operating activities | $21.596 million | $17.358 million |
| Cash, cash equivalents and deposits | $66.596 million | $26.609 million |
| Total assets | $75.847 million | $33.752 million |
| Total shareholders’ equity (deficit) | $72.777 million | $(87.632) million |
Cash and cash equivalents alone were $4.319 million at year-end; most liquid resources were held in short- and long-term deposits. Current assets were $47.200 million versus current liabilities of $2.877 million. The filing reports no significant borrowing or material financing commitments other than leases. Lease obligations totaled $4.403 million. No operating margin is meaningful because the company had no product revenue.
Cash used in investing activities was $40.768 million, principally reflecting purchases of short- and long-term deposits; financing provided $62.774 million, chiefly from the IPO. The company reported an accumulated deficit of $132.286 million. The financial statements received an unqualified U.S. GAAP audit opinion. The auditor did not attest to internal control over financial reporting.
Material changes versus FY2019
- Operating loss increased by $7.712 million, reflecting higher R&D, marketing/business development, and G&A spending as Phase 3 activity expanded and public-company costs rose.
- Net loss increased substantially, principally because financial expense shifted to $10.597 million from $11.655 million of financial income in 2019. The 2020 expense included an $11.373 million non-cash warrant revaluation; the prior-year income included an $11.365 million warrant revaluation gain.
- FY2020 included a $2.114 million deemed dividend arising from Series E-1 conversion price-protection rights. The filing reports net loss attributable to ordinary shares of $38.983 million in its MD&A, while the financial statements’ EPS calculation includes preferred-share preference and the deemed dividend in its numerator.
- The June 2020 IPO raised $62.757 million net. Preferred shares converted into ordinary shares; year-end ordinary shares outstanding were 18,494,739, versus 562,748 at year-end 2019.
Outlook, risks and unusual items
- Management expected year-end cash, cash equivalents and deposits to fund operations and capital expenditures for at least 12 months from the filing date and to support completion and reporting of SHIELD I results. Additional capital was expected to be needed for SHIELD II, resumption of the sternal Phase 3 trial, and any commercialization.
- SHIELD I began in July 2020 and SHIELD II in December 2020 for abdominal surgery SSIs; topline SHIELD I results were expected at the end of 2021. The sternal SSI Phase 3 trial’s enrollment was paused in April 2020 amid COVID-19 and prioritization of the abdominal trials. These timelines and expectations are forward-looking and not assurances of success.
- Management expects continuing losses and rising expenses. Major risks include clinical efficacy or safety outcomes, patient enrollment, regulatory review and the proposed 505(b)(2) pathway, manufacturing scale-up and compliance, third-party supply, market acceptance and reimbursement, competition, and access to further financing. COVID-19 could delay trials and affect operations or capital access.
- Israeli Innovation Authority grants carry potential royalties of 3% on applicable product sales, up to grant amounts plus interest, and restrictions on transferring certain technology or manufacturing outside Israel. The reported contingent grant-related amount was approximately $5.139 million.
- A January 2020 automatic filling-machine agreement totaled EUR 1.326 million; a EUR 0.372 million prepayment had been made, with remaining payments expected during 2021. A related-party CRO agreement for Phase 3 work had a total value of approximately $6.3 million; $0.717 million was paid in 2020.
- A prior $250,000 finder’s-fee lawsuit was dismissed in the company’s favor in April 2020. The company reported no current material legal proceedings. It has never paid dividends and does not expect to do so in the foreseeable future.
- The company warned it may be classified as a PFIC for U.S. tax purposes. It also disclosed currency exposure: approximately 70% of expenses were NIS-denominated, with partial hedging.
Most important facts for investors to verify
- Whether SHIELD I and SHIELD II enroll and produce results on schedule, and whether pivotal-trial outcomes support regulatory submissions and the intended label.
- Current cash, deposits, operating cash burn, and financing needs relative to trial costs and the stated runway; distinguish cash from deposits and restricted cash.
- Whether the warrant-related non-cash charge, deemed dividend, and reported per-share loss are correctly understood when comparing earnings and dilution.
- Manufacturing readiness, regulatory inspection status, and the cost and timing of commercial process validation and the filling-machine commitment.
- Potential IIA royalty and technology-transfer obligations, related-party CRO terms, share-based compensation and dilution, and the company’s PFIC status for the relevant tax year.